While many reports have advocated that KRAS is a negative prognostic marker, others have observed no prognostic significance, and few studies have addressed the prevalence and prognostic impacts of KRAS mutations in Saudi patients with CRC [7-11]. Therefore, the present study aimed to address the prevalence of KRAS mutations and evaluate their impact on clinical outcomes (if any) among Saudi patients seeking advice at a tertiary oncology center. The gene discussed is KRAS; the disease is colorectal carcinoma.